Europäische Union - Rumänisch - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - leucemie, mieloidă, acută - agenți antineoplazici - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Republik Moldau - Rumänisch - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

berlin-chemie ag (menarini group) - o combinatie - solutie perfuzabila - 100 mg/ml

Republik Moldau - Rumänisch - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

berlin-chemie ag (menarini group) - o combinatie - solutie perfuzabila - 100 mg/ml

Republik Moldau - Rumänisch - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bayer ag - levonorgestrelum - sistem cu cedare intrauterina - 13,5 mg

Europäische Union - Rumänisch - EMA (European Medicines Agency)

n.v. organon - acetat de nomegestrol, estradiol - contracepţia - hormoni sexuali și modulatori ai sistemului genital, - contracepție orală.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - febra hemoragica ebola - vaccinuri - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - febra hemoragica ebola - vaccinuri - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningită, meningococică - vaccinuri - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

roche registration gmbh - baloxavir marboxil - gripa, umană - antivirale pentru uz sistemic - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.

Europäische Union - Rumänisch - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - infecții pneumococice - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. vezi secțiunile 4. 4 și 5. 1 pentru informații privind protecția împotriva serotipurilor pneumococice specifice. the use of vaxneuvance should be in accordance with official recommendations.